WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

New England Journal of Medicine publishes COVID-19 treatment trial results

Details
Research
15 January 2021
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.
Read more ...

Scientists identify 'immune cop' that detects SARS-CoV-2

Details
Research
13 January 2021
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an antiviral response. The study, published today in Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19.
Read more ...

New findings help explain how COVID-19 overpowers the immune system

Details
Research
11 January 2021
Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondria are one of the first lines of defense against COVID-19 and identifies key differences in how SARS-CoV-2, the virus that causes COVID-19, interacts with mitochondrial genes when compared to other viruses.
Read more ...

New virtual screening strategy identifies existing drug that inhibits COVID-19 virus

Details
Research
31 December 2020
A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational Biology.
Read more ...

Sustained cellular immune dysregulation in individuals recovering from COVID-19

Details
Research
29 December 2020
COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.

Many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease with atypical pneumonia and multiple system organ failure.

Read more ...

How SARS-CoV-2 interacts with cells

Details
Research
22 December 2020
SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the molecular interactions between the virus and the cells it infects. It must also be clarified, whether these interactions favour the multiplication of the virus or - on the contrary - activate defence mechanisms.
Read more ...

Neutralizing antibodies protect against severe COVID-19

Details
Research
18 December 2020
Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular interest are neutralizing antibodies, which can block the virus from entering and infecting human cells, helping the immune system clear the virus and prevent future infections.
Read more ...

More Pharma News ...

  1. ACE2 protein protects against severe COVID-19
  2. Remdesivir likely to be highly effective antiviral against SARS-CoV-2
  3. Oral drug blocks SARS-CoV-2 transmission
  4. Study finds metformin reduced COVID-19 death risks in women
  5. KU Leuven vaccine candidate protects against COVID-19 and yellow fever
  6. Predict cellular drug targets against COVID-19
  7. Doctors use existing treatment earlier to save the lives of COVID-19 patients
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Research
  4. Vitamin D linked to low virus death rate

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.